Drug Trial Radar · NCT00077675
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Last checked: Nov 19, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
201
Actual
Start
Feb 2004
Primary completion
Sep 2004
Study completion Sep 2004
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
Conditions
- Infections, Gram-positive Bacterial
Interventions
TelavancinDrug
Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
vancomycin or antistaphylococcal penicillinDrug
Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) PopulationTime frame: 7 to 14 days following completion of antibiotic treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Paradise Valley Hospital, 2400 E. 4th Street
National City, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.